2nd Antibody and Fusion Protein Engineering and Developability Summit

Engineering Safety and Developability for Complex Antibody-Based Therapeutics.

The Antibody and Fusion Protein Engineering and Developability Summit returns as the protein developers' playbook on selecting and engineering the billion-dollar candidate, that can pair the right biology with a smooth progression through development.

Uniting 80+ protein and antibody discovery leads, development scientists and antibody engineers, the Summit will equip you to take the guess work out of fusion and antibody-derived protein drug development, reducing drug development cost and time which has never been so important than in today's funding environment.


URLs:
Website: https://go.evvnt.com/2291577-0?pid=10018
Tickets: https://go.evvnt.com/2291577-2?pid=10018
Brochure: https://go.evvnt.com/2291577-3?pid=10018

Prices:
Drug Developer Pricing - Industry Pricing: USD 2999.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3598.00,
Drug Developer Pricing - Conference + 2 Workshops: USD 4197.00,
Academic Pricing - Conference Only: USD 2599.00,
Academic Pricing - Conference + 1 Workshop: USD 3098.00,
Academic Pricing - Conference + 2 Workshops: USD 3597.00,
Vendor Pricing - Conference Only: USD 3699.00,
Vendor Pricing - Conference + 1 Workshop: USD 4398.00,
Vendor Pricing - Conference + 2 Workshops: USD 5097.00

Speakers: Abhinav Gupta, Senior Scientist I, AI Innovation-Antibody, Sanofi, Brian Hall, Head of Biologics Characterization, Expression and Purification Distinguished Scientist, Sanofi, Christopher Wassif, Director - Molecular Engineering and Antibody Technologies, AstraZeneca, Horacio Nastri, Vice President - Protein Science and Technology, Incyte, Jane Guo, Principal Scientist/Lab Head, Sanofi, Jeffrey Way, President, Wyss Institute at Harvard University, Jessica Wiwczar, Senior Scientist II Bioprocess And Early Development Protein Sciences, Invenra Inc., Jijun Dong, Chief Scientific Officer, Salubris Biotherapeutics, Jinsam You, Vice President Of Development, INGENIA Therapeutics, Joel Cohen-Solal, Principal Scientist, Fc Biology, Abbvie, Julien Lafrance-Vanasse, Senior Principal Scientific Researcher in Antibody Engineering, Genentech, Kevin Dagbay, Principal Scientist, Keros Therapeutics, Michael Dyson, Vice President - Antibody Discovery and Engineering, Ichnos Science, Nina Weisser, Director - Multispecific Antibody Therapeutics, Zymeworks, Paula Fraenkel, Executive Director - Global Project and Oncology Lead, AstraZeneca, Rajika Perera, Co-Founder and Chief Executive Officer, Poseidon LLC, Roee Ramot, Senior Scientist II, Antibody Discovery Scientist and Automation, Novartis, Rosa Grenha, Director of Protein Biochemistry, Keros Therapeutics, Sagar Kathuria, Senior Principal Scientist, Sanofi, Sasha Ebrahimi, Principal Investigator, GlaxoSmithKline Plc, Thach Mai, Director of Discovery and Platform, Juvena Therapeutics, Wenhua Wang, Senior Staff Scientist, Regeneron